Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Hana Biosciences Charts. Click Here for more Hana Biosciences Charts.](/p.php?pid=staticchart&s=A%5EHBX&p=8&t=15)
Hana Biosciences (AMEX: HBX), a South San
Francisco-based biopharmaceutical company focused on advancing cancer
care, will present at the C.E. Unterberg, Towbin Emerging Growth Life
Sciences Conference on Tuesday, Oct. 25, 2005, at 2:20 p.m. The
presentation will take place in Room A at the New York Palace Hotel at
455 Madison Ave., New York, New York.
Mark Ahn, Ph.D., president and CEO of Hana Biosciences, will
provide a company overview including a comprehensive discussion of the
company's unique oncology pipeline which includes Zensana(R), an oral
spray version of the popular antiemetic Zofran with commercialization
anticipated in early 2007. The presentation will also include
information on the promising anti-cancer agent, Talotrexin, and the
potentially powerful radiation sensitizer currently in Phase I
clinical trials.
The C.E. Unterberg, Towbin Emerging Life Sciences Conference
features more than 60 emerging leaders in the life science,
diagnostics, med tech, specialty pharmacy and medical device
industries.
About Hana Biosciences
Hana Biosciences Inc. is a South San Francisco, Calif.-based
biopharmaceutical company that acquires, develops, and commercializes
innovative products to advance cancer care. The company is committed
to creating value by building a world-class team, accelerating the
development of lead product candidates, expanding its pipeline by
being the alliance partner of choice, and nurturing a unique company
culture. Additional information on Hana Biosciences can be found at
www.hanabiosciences.com.
This press release contains forward-looking statements that
involve risks and uncertainties that could cause Hana's actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual outcomes
and results to differ materially from these statements. Among other
things, there can be no assurances that any of Hana's development
efforts relating to its product candidates will be successful. Other
risks that may affect forward-looking information contained in this
press release include the possibility of being unable to obtain
regulatory approval of Hana's product candidates, the risk that the
results of clinical trials may not support Hana's claims, Hana's
reliance on third-party researchers to develop its product candidates
and its lack of experience in developing pharmaceutical products.
Additional risks are described in the company's Annual Report on Form
10-KSB for the year ended Dec. 31, 2004. Hana assumes no obligation to
update these forward-looking statements, except as required by law.